Surgery for Pancreatic Cancer: Recent Controversies and Current Practice

Wray, Curtis J.; Ahmad, Syed A.; Matthews, Jeffrey B.; Lowy, Andrew M.

doi:10.1053/j.gastro.2005.03.035

Cited by 228 publications

(181 citation statements)

References 94 publications

Supporting

Mentioning

164

Contrasting

Unclassified

Order By: Relevance

“…Pancreatic cancer is considered to be a lethal solid tumor, and its 5-year survival rate is less than 5%. Although the only curative treatment for pancreatic cancer is surgical resection, more than 80% of patients with pancreatic cancer have a locally advanced or metastatic tumor that is unresectable at the time of diagnosis (1)(2)(3). The clinical symptoms of pancreatic cancer are usually unremarkable until the cancer has progressed to an advanced stage.…”

Section: Introductionmentioning

confidence: 99%

A Novel Serum Metabolomics-Based Diagnostic Approach to Pancreatic Cancer

Kobayashi

Nishiumi

Ikeda

et al. 2013

Cancer Epidemiology, Biomarkers &Amp; Prevention

158

144

View full text Add to dashboard Cite

Background: To improve the prognosis of patients with pancreatic cancer, more accurate serum diagnostic methods are required. We used serum metabolomics as a diagnostic method for pancreatic cancer.Methods: Sera from patients with pancreatic cancer, healthy volunteers, and chronic pancreatitis were collected at multiple institutions. The pancreatic cancer and healthy volunteers were randomly allocated to the training or the validation set. All of the chronic pancreatitis cases were included in the validation set. In each study, the subjects' serum metabolites were analyzed by gas chromatography mass spectrometry (GC/MS) and a data processing system using an in-house library. The diagnostic model constructed via multiple logistic regression analysis in the training set study was evaluated on the basis of its sensitivity and specificity, and the results were confirmed by the validation set study.Results: In the training set study, which included 43 patients with pancreatic cancer and 42 healthy volunteers, the model possessed high sensitivity (86.0%) and specificity (88.1%) for pancreatic cancer. The use of the model was confirmed in the validation set study, which included 42 pancreatic cancer, 41 healthy volunteers, and 23 chronic pancreatitis; that is, it displayed high sensitivity (71.4%) and specificity (78.1%); and furthermore, it displayed higher sensitivity (77.8%) in resectable pancreatic cancer and lower false-positive rate (17.4%) in chronic pancreatitis than conventional markers.Conclusions: Our model possessed higher accuracy than conventional tumor markers at detecting the resectable patients with pancreatic cancer in cohort including patients with chronic pancreatitis.Impact: It is a promising method for improving the prognosis of pancreatic cancer via its early detection and accurate discrimination from chronic pancreatitis. Cancer Epidemiol Biomarkers Prev; 22(4); 571-9. Ó2013 AACR.

show abstract

Section: Introductionmentioning

confidence: 99%

A Novel Serum Metabolomics-Based Diagnostic Approach to Pancreatic Cancer

Kobayashi

Nishiumi

Ikeda

et al. 2013

Cancer Epidemiology, Biomarkers &Amp; Prevention

158

144

View full text Add to dashboard Cite

show abstract

“…Because this disease is characterized by extensive local invasion and early lymphatic and hematogenous metastasis (Wray et al 2005;Mann et al 2006), only 1-4% of all patients with the pancreatic cancer survive 5 years after diagnosis (Eckel et al 2006). Therefore, developing chemoprevention measures for pancreatic cancer is an important direction of research.…”

confidence: 99%

Selective Inhibition of Cyclooxygenase-2 Suppresses the Growth of Pancreatic Cancer Cells in Vitro and in Vivo

Xie

Wang

et al. 2008

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Cyclooxygenase-2 (COX-2), a prostaglandin synthetase, is involved in development of certain tumors. We therefore analyzed COX-2 expression in pancreatic cancer tissues (53 samples) and Panc-1 human pancreatic cancer cells by immunohistochemistry, RT-PCR and western-blotting analyses. Also, immunohistochemistry of proliferating cell nuclear antigen (PCNA) was performed. We found expression of COX-2 was dramatically upregulated in 36 of 53 cases (67.9%) and the expression of COX-2 was associated with the diameter (> 3 cm) of the tumors ( p < 0.05), but not with the age, gender, tumor location, differentiation, lymph-node metastases and TNM stage. The positivity rate of PCNA expression in the pancreatic cancer cells of the COX-2 positive group (32.88 ± 13.26%) was significantly higher than that in the COX-2 negative group (24.56 ± 11.51%) ( p < 0.05). Then we investigated the effect of selective inhibitors of COX-2 (NS398 and celecoxib) on proliferation of Panc-1 cells by 3-(4,5 dimethyl-2-thiazolyl)-2.5-diphenyl-2H-tetrazolium bromide (MTT) assay. Either NS398 or celecoxib suppressed proliferation of Panc-1 cells dose-dependently in vitro. Furthermore, Panc-1 cells were implanted into nude mice, and celecoxib was administrated orally with feed. The volume of the tumor xenografted into nude mice was decreased by 51.6% in the celecoxib group ( p < 0.01). In conclusion, the increased expression of COX-2 may be responsible for rapid proliferation of pancreatic cancer, and specific inhibition of COX-2 suppresses proliferation of Panc-1 cells in vitro and in nude mice. The selective inhibitor of COX-2 may be an effectual agent for pancreatic cancer chemoprevention.

show abstract

“…It is one of the challenging tumors to be cured, which death ratio almost equal to its occurrence ratio. To make better the prognosis, many therapies such as chemotherapy, radiotherapy, surgery or combine all these modalities have been used for pancreatic cancer treatment but the result is still not very good [6,7]. Beside it, these modalities which is using for pancreatic cancer also can cause many adverse effects such as reduced body weight due to orally taking cause disturbance, systemic toxic effect, lymphatic leakage and also effecting neighbor cells [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Liposomes and Nanotechnology in Drug Development: Focus On Pancreatic Cancer

Malik¹,

Jin²,

Raheem³

et al. 2017

JGPLD

View full text Add to dashboard Cite

Pancreatic cancer usually has high morbidity and mortality and rests one of the most challenging cancers to treat. 5 years survival rate is less than 6 percent overall for people with pancreatic cancer, because of very late diagnosis and absence of effective treatment. In a western world, pancreatic tumor is the fourth most common cause of death in a western world. The pancreatic tumor needs selective delivery of drugs to target cells, with no side effects is major goals of the recent investigations for the real treatment of the pancreatic tumor. Medication which targets pancreatic tumor cells specially and carriers which deliver medications to specific cells which are quickly dividing, development of these kind drugs is considered as magic for the management of pancreatic cancer. In latest years, liposomes and nanotechnology can show a vital character in the treatment of pancreatic tumor. Liposomes contain multiple characteristics, such as the ability to protect the material from degradation, the capacity for encapsulating many materials and capability for delivering materials intracellularly fusion with plasma membrane. Nanoparticles as a carrier offer a new style of delivery of the medications to target cells of a tumor and allow drugs for the binding to tumor cell membrane, to cytoplasmic and to nuclear receptor sites. It delivers high medication concentrations to specific cells with few side effects to other normal tissues. The general importance of this evaluation is to increase overall understanding of development of the therapeutic nanomedicine for the treatment of pancreatic tumors, agents delivered by nanoliposomes, liposomal nanomedicine in targeting cancer and safety issues.

show abstract

Surgery for Pancreatic Cancer: Recent Controversies and Current Practice

Cited by 228 publications

References 94 publications

A Novel Serum Metabolomics-Based Diagnostic Approach to Pancreatic Cancer

A Novel Serum Metabolomics-Based Diagnostic Approach to Pancreatic Cancer

Selective Inhibition of Cyclooxygenase-2 Suppresses the Growth of Pancreatic Cancer Cells in Vitro and in Vivo

Liposomes and Nanotechnology in Drug Development: Focus On Pancreatic Cancer

Contact Info

Product

Resources

About